LEADER 04080nam 2200445 450 001 9910820276303321 005 20210915042715.0 010 $a1-5381-1084-9 035 $a(CKB)4100000007151224 035 $a(MiAaPQ)EBC5845004 035 $a(Au-PeEL)EBL5845004 035 $a(OCoLC)1040077040 035 $a(PPN)260237159 035 $a(EXLCZ)994100000007151224 100 $a20210915d2018 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 14$aThe medical marijuana guide $ecannabis and your health /$fPatricia C. Frye with Dave Smitherman 210 1$aLanham, Maryland :$cRowman & Littlefield,$d[2018] 210 4$dİ2018 215 $a1 online resource (239 pages) 311 $a1-5381-1083-0 327 $aCover -- The Medical Marijuana Guide -- The Medical Marijuana Guide: Cannabis and Your Health -- Copyright page -- Contents -- Acknowledgments -- Introduction -- Chapter 1 -- History of Cannabis -- Agricultural Beginnings -- Ancient Medicine -- Western Medicine -- The New World -- Twentieth- and Twenty-First-Century Medicine, Regulations, and Politics -- Summary -- Chapter 2 -- Legalization -- Qualifying Conditions -- High CBD/Low THC -- No Access to Cannabis Medicine -- Federal Legislation -- Chapter 3 -- Cannabinoids, Terpenes, and Flavonoids -- The Cannabis Plant -- Other Components of the Cannabis Plant -- Synthetic Cannabinoids: Spice and K2 -- Pharmaceutical Cannabinoids -- Chapter 4 -- Laboratory Testing -- Infestation -- Toxins -- Residual Solvents -- Cannabinoids and Terpenes -- Pesticides and Heavy Metals -- What about Organic? -- Summary -- Chapter 5 -- Clinical Conditions -- Physical Pain -- Chronic Conditions -- Neurodegenerative Disorders -- Mental Health -- Other Benefits and Special Considerations -- Summary -- Chapter 6 -- Adverse Effects Associated with Cannabis Use for Medical Problems -- Lethal Dose -- Poor Metabolizers -- Intoxication -- Impaired Driving -- Psychosis -- Anxiety and Paranoia -- Gastrointestinal Effects -- Sedation -- Appetite -- Cardiovascular Effects -- Respiratory Effects -- Infection -- Fertility -- Pregnancy -- Testicular Cancer -- Tolerance -- Nervous System -- Neurodevelopmental -- Drug Interactions -- Possible Consequences of Overuse -- Summary -- Chapter 7 -- First Doctor's Visit -- How to Decide on a Cannabis Doctor -- Preparing for Your Visit -- When You Arrive -- Your Visit with the Doctor -- Chapter 8 -- Ways to Medicate -- Keeping Track of What You Use and How You Respond -- Deciding on Your Delivery System -- The Biphasic Effect -- When Will It Start Working, and How Long Will It Last?. 327 $aOverdose -- Chapter 9 -- Making Your Own Medicine -- Growing Your Own -- Making Tinctures -- Making Edibles -- Chapter 10 -- Hemp-Derived Cannabidiol (CBD) -- Chapter 11 -- Self-Care -- Nicotine -- Diet -- Suggestions for Enhancing Your Endocannabinoid Tone and Decreasing Inflammation -- Appendix -- Lists of Drugs by Metabolism1 -- Drugs Metabolized by CYP2C9 -- Drugs Metabolized by CYP2C19 -- Drugs Largely Metabolized by 3A4, 2C9, and 2C19 -- Drugs Metabolized by Both 3A4 and 2C9 -- Drugs Metabolized by Both 3A4 and 2C19 -- 3A4 Inhibitors -- 2C9 Inhibitors -- 3A4 Inducer -- Notes -- Chapter 1 -- Chapter 2 -- Chapter 3 -- Chapter 4 -- Chapter 5 -- Chapter 6 -- Chapter 8 -- Chapter 10 -- Chapter 11 -- Appendix -- Works Cited -- Index -- About the Author -- About the Author. 330 $aOffering an accessible guide to the use of cannabis in medical care, this work sheds light on the role of medical marijuana in treating everything from chronic pain to terminal illnesses. 606 $aMarijuana$xTherapeutic use 615 0$aMarijuana$xTherapeutic use. 676 $a615.323648 700 $aFrye$b Patricia C.$01636616 702 $aSmitherman$b Dave 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910820276303321 996 $aThe medical marijuana guide$93977966 997 $aUNINA LEADER 02817nam 2200529 450 001 9910830576003321 005 20230808205305.0 010 $a1-119-31855-6 010 $a1-119-31854-8 010 $a1-119-31833-5 035 $a(CKB)4330000000010219 035 $a(EBL)4560563 035 $a(MiAaPQ)EBC4560563 035 $a(EXLCZ)994330000000010219 100 $a20160714h20162016 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aEyestrain reduction in stereoscopy /$fLaure Leroy 210 1$aLondon, [England] ;$aHoboken, New Jersey :$cISTE :$cWiley,$d2016. 210 4$dİ2016 215 $a1 online resource (165 p.) 225 1 $aFocus Series 300 $aDescription based upon print version of record. 311 $a1-84821-998-9 320 $aIncludes bibliographical references and index. 327 $aIntro; Table of Contents; Title; Copyright; Acknowledgments; Introduction; 1 Principles of Depth and Shape Perception; 2 Technological Elements; 3 Causes of Visual Fatigue in Stereoscopic Vision; 4 Short- and Long-term Consequences; 5 Measuring Visual Fatigue; 6 Reducing Spatial Frequencies; 7 Reducing the Distance Between the Virtual Cameras; Conclusion; Bibliography; Index; End User License Agreement; 1.1. Function of the eye; 1.2. Depth perception without stereoscopy; 1.3. Depth perception through stereoscopic vision; 1.4. Perception of inclinations and curves 327 $a1.5. Artificial stereoscopic vision2.1. Taking a picture; 2.2. Reproduction; 2.3. Motion parallax restitution; 3.1. Conflict between accommodation and convergence; 3.2. Too much depth; 3.3. High spatial frequencies; 3.4. High temporal frequency; 3.5. Conflicts with monoscopic cues; 3.6. Vertical disparities; 3.7. Improper device settings; 4.1. Short-term effects; 4.2. Long-term consequences; 5.1. Visual acuity; 5.2. Proximum accommodation function; 5.3. Ease of accommodation; 5.4. Stereoscopic acuity; 5.5. Disassociated heterophorias; 5.6. Fusional reserves; 5.7. Subjective tests 327 $a6.1. Principle6.2. Technical solution; 6.3. Experiment; 6.4. Measurements of fatigue taken; 6.5. Result; 7.1. Principle; 7.2. Experiment; 7.3. Results; 7.4. Discussion 410 0$aFocus series (London, England) 606 $aEyestrain 606 $aEyestrain$xPrevention 606 $aThree-dimensional display systems 615 0$aEyestrain. 615 0$aEyestrain$xPrevention. 615 0$aThree-dimensional display systems. 676 $a617.7 700 $aLeroy$b Laure$01343750 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830576003321 996 $aEyestrain reduction in stereoscopy$94085362 997 $aUNINA